Department of Dermatology and Venereology, School of Medicine, Hacettepe University, Ankara, Turkey.
Australas J Dermatol. 2021 Feb;62(1):e83-e85. doi: 10.1111/ajd.13391. Epub 2020 Jul 7.
Recent reports indicate that hydroxychloroquine is a potential new treatment option for alopecia universalis; thus, we aimed to report on the safety and efficacy of hydroxychloroquine in 6 patients with refractory alopecia universalis that were treated with 400 mg/d continuously for ≥6 months. The treatment outcome was retrospectively evaluated using the Severity of Alopecia Tool (SALT), and at the end of 6 months, patients with a ≥50% decrease in the SALT score were considered as strong responders, a 5%-50% decrease as intermediate responders and a <5% decrease as non-responders. The present findings indicate that hydroxychloroquine is not an effective treatment since in 5 of the 6 patients it was discontinued at the end of 6 months due to lack of hair regrowth, whereas only a 6-year-old boy responded with a SALT score change of 8% after the 12th month.
最近的报告表明,羟氯喹可能是一种治疗普秃的新方法;因此,我们旨在报告 6 例对普秃难治的患者应用羟氯喹(400mg/d,连续使用≥6 个月)的安全性和疗效。采用脱发严重程度评分工具(SALT)对治疗结果进行回顾性评估,6 个月结束时,SALT 评分下降≥50%者为强应答者,下降 5%-50%者为中应答者,下降<5%者为无应答者。本研究结果表明,羟氯喹并非有效治疗方法,因为在 6 例患者中,有 5 例在 6 个月时因无毛发再生而停药,而仅 1 例 6 岁男孩在第 12 个月时 SALT 评分改变 8%。